SEC Form 4 · accession 0001209191-18-017227
TEVA PHARMACEUTICAL INDUSTRIES LTD · TEVA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Gianfranco Nazzi
Officer — EVP, Growth Markets Commercial
Period of report
Mar 3, 2018
Accepted (ET)
Mar 6, 2018 · 4:18 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000818686
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1,F2 | Mar 3, 2018 | M | 1,399 | — | A | 5,644 | D | |
| Ordinary SharesF1 | Mar 5, 2018 | F | 732 | $19.28 | D | 4,912 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Share UnitsF2,F3,F1 | — | Mar 3, 2018 | M | 1,399 | D | — | — | Ordinary Shares | 1,399 | 4,198 | D |
Explanation of responses
- F1The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
- F2Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
- F3Restricted share units were granted on March 3, 2017, with 1,399 vesting on each of March 3, 2018, March 3, 2019 and March 3, 2020 and 1,400 vesting on March 3, 2021.